The difference between building a company and pumping a stock can become more obvious by looking at how owners of the stock judge the company’s promotional activity.
Isco.OB undertook the Christmas marketing plan for its subsidiary line of skincare products. While the company was urging buyers to buy product thereby generating revenues for the company, improving its bottom line, and sending it closer to EBITDA, one of the retail holders of the stock complained on its Yahoo discussion board that the company should have the instead been trying to promote the fact that it’d been able to promote itself on Fox news. While some sellers of slice or dice your Gee whiz it does even more but wait operators are standing by now garbage retail products may in fact desire the famous “as seen on TV” to be the Mark of worth, in the world of business stockholders are better served when the CEO appears on television to explain how he will work to reduce the tax liabilities.
Isco.OB has been a dog for much of 2011. This does not change the fact that out of the three “pure plays” in the stem sector Isco remains the number one chance at achieving EBITDA. Gern may become an interesting turnaround play in 2012, since it has formally abandoned its position as a stem play. As a cancer play its present price may attract the prudent speculator.
Full disclosure: clients and Isco OB at under 15/16. Clients in gern overloaded at 1 13/32
When volume and momentum pickup on Isco.OB I expect to be recommending it again .
Posted under business
This post was written by admin on December 20, 2011
